Cancer Treatment market research reports by DelveInsight

• Metastatic HR+/HER2− Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 9,500

  Metastatic HR+/HER2− Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2032 Key Highlights Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The HR+/HER2- subtype is the most common of all the breast cancer subtypes. The total market size in ... Read More

• Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032 Key Highlights Non-metastatic prostate cancer (nmPC) refers to prostate cancer that has not spread beyond the prostate gland and nearby lymph nodes. It is a localized form of prostate cancer. When prostate ... Read More

• Triple Negative Breast Cancer Epidemiology Forecast - 2032

  Sep 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Triple Negative Breast Cancer Epidemiology Forecast - 2032 Key Highlights Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The classification of these subtypes has evolved over the years. The most common and widely accepted classification of breast cancer i ... Read More

• Cutaneous T-Cell Lymphoma (CTCL)- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Cutaneous T-Cell Lymphoma (CTCL)- Pipeline Insight, 2023 DelveInsight’s, “Cutaneous T-Cell Lymphoma (CTCL)- Pipeline Insight, 2023” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Cutaneous T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, ... Read More

• T cell Lymphoma -Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  T cell Lymphoma -Pipeline Insight, 2023 DelveInsight’s, “T-cell Lymphoma -Pipeline Insight, 2023” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage p ... Read More

• Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023 DelveInsight’s, “Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline d ... Read More

• Chemotherapy-induced peripheral neuropathy - Epidemiology Forecast - 2032

  Jun 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Chemotherapy-induced peripheral neuropathy - Epidemiology Forecast - 2032 Key Highlights Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. ... Read More

• Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-inhibitors – Market Insights, Epidemiology and Market Forecast – 2032

  Jun 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-inhibitors – Market Insights, Epidemiology and Market Forecast – 2032 Key Highlights: In Japan, the contribution of KRAS mutations is lower compared to Western countries like the United States and Europe In the United States, KRASG12C is present in ~ ... Read More

• Triple Negative Breast Cancer - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  Triple Negative Breast Cancer - Pipeline Insight, 2023 DelveInsight’s, “Triple Negative Breast Cancer - Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles ... Read More

• Anal Cancer - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,250

  Anal Cancer - Pipeline Insight, 2023 DelveInsight’s, “Anal Cancer - Pipeline Insight, 2023” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Anal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It a ... Read More

• Ovarian Cancer- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  Ovarian Cancer- Pipeline Insight, 2023 DelveInsight’s, “Ovarian Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage pro ... Read More

• Metastatic Uveal Melanoma - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Metastatic Uveal Melanoma - Pipeline Insight, 2023 DelveInsight’s, “Metastatic Uveal Melanoma - Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Metastatic Uveal Melanoma pipeline landscape. It covers the pipeline drug profiles, including ... Read More

• Chemotherapy Drugs- Market Insights, Competitive Landscape, and Market Forecast - 2027

  Mar 01, 2023  |  Published by: DelveInsight  |  USD 2,750

  Chemotherapy Drugs- Market Insights, Competitive Landscape, and Market Forecast - 2027 Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer ... Read More

• Angioimmunoblastic T-cell lymphoma - Pipeline Insight, 2023

  Mar 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Angioimmunoblastic T-cell lymphoma - Pipeline Insight, 2023 DelveInsight’s, “Angioimmunoblastic T cell Lymphoma – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angioimmunoblastic T cell Lymphoma pipeline landscape. It covers the pipelin ... Read More

• HR Positive/ HER2 Negative Breast Cancer- Pipeline Insight, 2023

  Mar 01, 2023  |  Published by: DelveInsight  |  USD 2,500

  HR Positive/ HER2 Negative Breast Cancer- Pipeline Insight, 2023 DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It cov ... Read More

• HPV Testing and Pap Test- Market Insights, Competitive Landscape, and Market Forecast - 2027

  Feb 01, 2023  |  Published by: DelveInsight  |  USD 2,750

  HPV Testing and Pap Test- Market Insights, Competitive Landscape, and Market Forecast - 2027 HPV Testing And PAP Test Market By Test Type (Primary HPV Testing, Co-Testing, And Pap Test), By Application (Cervical Cancer, Vaginal Cancer, And Others), By Technology Type (Polymerase Chain Reaction, And ... Read More

• Chemotherapy induced diarrhea - Market Insight, Epidemiology And Market Forecast - 2032

  Jan 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Chemotherapy induced diarrhea - Market Insight, Epidemiology And Market Forecast - 2032 DelveInsight’s “Chemotherapy-induced Diarrhea (CID) – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the CID, historical and forecasted epidemiology as wel ... Read More

• KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032

  Dec 01, 2022  |  Published by: DelveInsight  |  USD 2,750

  KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032 “KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032” report provides comprehensive insights about KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the KEYTRUDA (pembrolizu ... Read More

• FASLODEX Drug Insight and Market Forecast – 2032

  Dec 01, 2022  |  Published by: DelveInsight  |  USD 2,750

  FASLODEX Drug Insight and Market Forecast – 2032 “FASLODEX Drug Insight and Market Forecast – 2032” report provides comprehensive insights about FASLODEX for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the FASLODEX for ER+ve HER2-ve Breast Cancer in the United States for ... Read More

• Breast Cancer Diagnostics- Market Insights, Competitive Landscape and Market Forecast–2027

  Dec 01, 2022  |  Published by: DelveInsight  |  USD 2,750

  Breast Cancer Diagnostics- Market Insights, Competitive Landscape and Market Forecast–2027 Breast Cancer Diagnostics Market By Product Type (Instrument, Reagent, And Consumables), By Type (Imaging, Lab Test), By End-User Type (Hospitals, Diagnostic Laboratories, Cancer Research Centers, Others), and ... Read More

• Blood Cancer Diagnostics Market Insights, Competitive Landscape and, Market Forecast - 2027

  Nov 01, 2022  |  Published by: DelveInsight  |  USD 2,750

  Blood Cancer Diagnostics Market Insights, Competitive Landscape and, Market Forecast - 2027 BLOOD CANCER DIAGNOSTICS MARKET BY TYPE (PRODUCTS [INSTRUMENTS, ASSAY KITS AND REAGENTS] AND SERVICES) TEST TYPE (BLOOD TESTS, IMAGING TESTS, BIOPSY, AND MOLECULAR TESTS), BY END-USER (HOSPTIALS, CLINICS, AND ... Read More

• Peritoneal Cancer - Pipeline Insight, 2022

  Nov 01, 2022  |  Published by: DelveInsight  |  USD 2,500

  Peritoneal Cancer - Pipeline Insight, 2022 DelveInsight’s, “Peritoneal cancer – Pipeline Insight, 2022,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Peritoneal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical ... Read More

• Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2022

  Nov 01, 2022  |  Published by: DelveInsight  |  USD 1,500

  Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2022 DelveInsight’s, “Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline ... Read More

• HER2 Positive Gastric Cancer - Pipeline Insight, 2022

  Nov 01, 2022  |  Published by: DelveInsight  |  USD 1,500

  HER2 Positive Gastric Cancer - Pipeline Insight, 2022 DelveInsight’s, “HER2 Positive Gastric Cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, i ... Read More

• Marginal Zone Lymphoma - Pipeline Insight, 2022

  Nov 01, 2022  |  Published by: DelveInsight  |  USD 2,500

  Marginal Zone Lymphoma - Pipeline Insight, 2022 DelveInsight’s, “Marginal Zone Lymphoma - Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical ... Read More

< prev 4 5 6 7 8 9 10 11 12 13 next >